Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics reported its provisional Q4 2023 consolidated financial results with revenue of KRW 1.07T and operating profit of KRW 350.0B, achieving an annual cumulative revenue of KRW 3.69T (+23.10% YoY) for 2023.
📊 [Key Disclosure Details & Financial Figures]
- Outlook Classification: Q4 2023 and Annual Cumulative Consolidated Provisional Business Results (Unit: KRW Million)
- Q4 2023 Quarterly Performance:
- Revenue: KRW 1,073,509M (+3.82% QoQ, +11.18% YoY)
- Operating Profit: KRW 349,968M (+9.87% QoQ, +11.88% YoY)
- Profit Before Income Tax Expenses: KRW 355,712M (+12.46% QoQ, -10.53% YoY)
- Net Profit: KRW 290,684M (+20.93% QoQ, -21.42% YoY)
- FY2023 Annual Cumulative Performance:
- Revenue: KRW 3,694,589M (+23.10% YoY)
- Operating Profit: KRW 1,113,680M (+13.22% YoY)
- Profit Before Income Tax Expenses: KRW 1,119,987M (+11.00% YoY)
- Net Profit: KRW 857,691M (+7.47% YoY)
- Release Target & Date: Domestic and foreign investors, media, etc. / January 24, 2024 (Provided by IR Team)
- Other Remarks:
- Samsung Bioepis was included as a consolidated subsidiary in Q2 2022 (accounted for via equity method until April 2022, consolidated from May 2022)
- Figures are preliminary prior to external audit completion and are subject to change
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Final Audit Figures and Subsequent Audit Report Disclosure
This disclosure provides advance fair disclosure regarding the provisional Q4 and full-year consolidated business results for FY2023. Checking whether these preliminary figures (full-year revenue of KRW 3.69T and operating profit of KRW 1.11T) are confirmed without adjustments following external audit completion is essential to evaluate the final accuracy of the reported financial data. Investors can verify the finalized figures through the upcoming ‘Submission of Audit Report’ filing and the Annual Report.
📢 Disclaimer and Source Notice
Source: This content was structured and newly generated based on official submission data from the Financial Supervisory Service DART system.
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial liabilities rest entirely with the individual investor.
Contact: For regulatory compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
